drugset
drugset / Trial / NCT04770428

Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers

NCT04770428 ↗

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate safety, tolerability, pharmacokinetics and immunogenicity of MEDI7352 in healthy participants.

Timeline

Start
2021-04-20
Primary completion
2021-12-02
Completion
2021-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI7352 Unknown 1.5 ml Subcutaneous

Indications

osteoarthritis, knee